Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 11/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | LDHB | P07195 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5880970 | 0.94 | PDE4A (0.34) | LDHAOPRD1LDHBALDH1A1 | |
| SCHEMBL3987507 | 0.88 | LDHA (0.40) | LDHALDHB | |
| SCHEMBL5880951 | 0.86 | LDHA (0.36) | LDHALDHBMEN1KMT2A | |
| SCHEMBL13939613 | 0.86 | LDHA (0.33) | LDHAOPRD1LDHBALDH1A1KMT2A | |
| SCHEMBL3993834 | 0.86 | ALDH1A1 (0.35) | LDHAOPRD1ALDH1A1MEN1KMT2A | |
| SCHEMBL3988700 | 0.86 | OPRD1 (0.36) | OPRD1ALDH1A1MEN1KMT2AKDM1A | |
| SCHEMBL3988555 | 0.86 | KMT2A (0.33) | LDHAOPRD1LDHBALDH1A1MEN1 | |
| SCHEMBL5880904 | 0.86 | PDE5A (0.32) | LDHAOPRD1LDHBKMT2A | |
| SCHEMBL3988478 | 0.86 | TP53 (0.35) | LDHAOPRD1ALDH1A1MEN1KMT2A | |
| SCHEMBL5881118 | 0.85 | LDHA (0.34) | LDHALDHBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115658-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase | AGOURON PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20040023958-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2004-02-05 | — | — | US | disclosed |
| WO-2003095441-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023958-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | POLRMT, RNGTT, RNASE1 | LDHA 2373/4885OPRD1 1937/4885LDHB 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.